Gm2 Gangliosidoses Stocks List
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
BBC | D | Virtus LifeSci Biotech Clinical Trials ETF | 0.43 | |
TXSS | B | Texas Small Cap Equity Index ETF | 0.28 | |
IWC | B | iShares Microcap ETF | 0.09 | |
FESM | B | Fidelity Enhanced Small Cap ETF | 0.06 | |
IBBQ | D | Invesco Nasdaq Biotechnology ETF | 0.05 |
Compare ETFs
Date | Stock | Title |
---|---|---|
Nov 15 | TSHA | Taysha Gene Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags |
Related Industries:
Biotechnology
- Gm2 Gangliosidoses
Gm2 Gangliosidoses is a group of rare, inherited disorders caused by the buildup of a fatty substance called GM2 ganglioside in the body's cells. This buildup can cause a wide range of symptoms, including intellectual disability, seizures, movement problems, and vision and hearing loss. Treatment is supportive and may include physical, occupational, and speech therapy, as well as medications to control seizures.
Popular Now
Recent Comments
- TraderMike on BOOT
- Dr_Duru on BOOT
- TraderMike on Stochastic Reached Oversold
- SuccessfulGrasshopper897 on Stochastic Reached Oversold
- Cos3 on Adding float as advanced filter criteria?
From the Blog
Featured Articles